Sangamo BioSciences, Inc. (SGMO) Special Call October 3, 2011 08:30 ET Executives Dr. Elizabeth Wolffe – Senior Director of Corporate Communications Edward Lanphier – President and Chief Executive Officer Dale Ando – Vice President, Therapeutic Development and Chief Medical Officer Analysts Charles Duncan – JMP Securities Liana Moussatos – Wedbush Chad Messer – Piper Jaffray PresentationOperator
Good morning and welcome to the Sangamo BioSciences Teleconference to discuss data from the company’s Phase 2b clinical trial subject to the diabetic neuropathy. This call is being recorded. I would now pass you over to the coordinator of this event, Dr. Elizabeth Wolffe, Senior Director of Corporate Communications. Dr. Elizabeth Wolffe – Senior Director of Corporate Communications Thank you, (Sharon). Good morning and thank you for joining Sangamo’s management team on our conference call to discuss top line data from the company’s Phase 2b clinical trial SB-509-901 which we released this morning. Also present during this call are several members of Sangamo’s senior management including Edward Lanphier, President and Chief Executive Officer; Geoff Nichol, Executive Vice President of Research and Development; Dale Ando, Vice President of Therapeutic Development and Chief Medical Officer; and Ward Wolff, Executive Vice President and Chief Financial Officer. Following this introduction, Edward and Dale will summarize the data and outline our products forward. Following that, we will open up the call for questions. As we begin, I’d like to remind everyone that the projections and forward-looking statements that we discuss during this conference call are based upon the information that we currently have available. This information will likely change over time. By discussing our current perception of the market and our future performance of Sangamo with you today, we are not undertaking an obligation to provide updates in the future.